用于临床前体内化合物筛选的高通量高容量核素成像
本文报道了在患者来源异种移植(PDX)小鼠模型中,用99mTc-三羰基法同时标记2-3种His标签蛋白,经静脉注射后行全身SPECT/CT成像与自动化图像分析,5周内对25种蛋白采集了超过500幅单动物图像,成像结果与离体数据相关性良好,全程质量控制与盲法自动化分析保障了数据可信度。
要点
- 5周内对25种蛋白采集超过500幅单动物SPECT图像,生成超过3500个ROI和超过1000项组织数据。
- 受试者间摄取变异典型值为13%(变异系数,COV)。
- 纵向成像较解剖实验大幅减少所需动物数,全部工作与分析在3个月内完成。
核心结论
- 来自75只小鼠、25种化合物的肿瘤、背景及全身摄取/清除大数据集可识别感兴趣的化合物。
- 纵向成像较解剖实验大幅减少所需动物数,全部实验工作与分析在3个月内完成,预期与药物开发计划相容。
- 全流程质量控制、成像合同研究组织对化合物特性设盲及自动化分析赋予数据集可信度。
- 额外离体数据可作为对照,但在同一中心未来研究中可省略。
研究设计与样本
- 临床前SPECT/CT成像方法学研究,在患者来源异种移植(PDX)小鼠模型中同时用99mTc-三羰基法标记2-3种His标签蛋白。
- 静脉注射剂量为20 nmol/kg、100 MBq,每组n=3。
- 注射后1、4、24小时采集3只小鼠同时全身SPECT/CT图像,对预选化合物延长至48小时和/或加做0-2小时动态SPECT。
- 器官摄取用自动化多图谱分割和手动分割定量,数据自动绘图、质控并存储于协作图像管理平台;离体摄取数据半自动收集并按成像数据分析。
主要发现
- 5周内对25种蛋白采集超过500幅单动物SPECT图像,最终生成超过3500个ROI和超过1000项组织数据。
- SPECT/CT图像在注射后48小时仍清晰显示肿瘤及其他组织摄取。
- 受试者间摄取变异典型值为13%(变异系数,COV)。
- 成像结果与离体数据相关性良好。
临床怎么用
- 全流程质量控制、成像合同研究组织对化合物特性设盲及自动化分析赋予数据集可信度。
- 额外离体数据可作为对照,但在同一中心未来研究中可省略。
- 对于更大化合物库,可加快放射性标记并调整成像时间点数量以提高周通量。
- 多图谱分割可通过SPECT/MRI扩展,但需MRI兼容的小鼠笼具。
- 临床试验中放射性药物的核素图像分析可能受益于所开发的自动化分析流程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical single-photon emission computed tomography (SPECT)/CT imaging studies are hampered by low throughput, hence are found typically within small volume feasibility studies. Here, imaging and image analysis procedures are presented that allow profiling of a large volume of radiolabelled compounds within a reasonably short total study time. Particular emphasis was put on quality control (QC) and on fast and unbiased image analysis. METHODS: 2-3 His-tagged proteins were simultaneously radiolabelled by 99mTc-tricarbonyl methodology and injected intravenously (20 nmol/kg; 100 MBq; n = 3) into patient-derived xenograft (PDX) mouse models. Whole-body SPECT/CT images of 3 mice simultaneously were acquired 1, 4, and 24 h post-injection, extended to 48 h and/or by 0-2 h dynamic SPECT for pre-selected compounds. Organ uptake was quantified by automated multi-atlas and manual segmentations. Data were plotted automatically, quality controlled and stored on a collaborative image management platform. Ex vivo uptake data were collected semi-automatically and analysis performed as for imaging data. RESULTS: >500 single animal SPECT images were acquired for 25 proteins over 5 weeks, eventually generating >3500 ROI and >1000 items of tissue data. SPECT/CT images clearly visualized uptake in tumour and other tissues even at 48 h post-injection. Intersubject uptake variability was typically 13% (coefficient of variation, COV). Imaging results correlated well with ex vivo data. CONCLUSIONS: The large data set of tumour, background and systemic uptake/clearance data from 75 mice for 25 compounds allows identification of compounds of interest. The number of animals required was reduced considerably by longitudinal imaging compared to dissection experiments. All experimental work and analyses were accomplished within 3 months expected to be compatible with drug development programmes. QC along all workflow steps, blinding of the imaging contract research organization to compound properties and automation provide confidence in the data set. Additional ex vivo data were useful as a control but could be omitted from future studies in the same centre. For even larger compound libraries, radiolabelling could be expedited and the number of imaging time points adapted to increase weekly throughput. Multi-atlas segmentation could be expanded via SPECT/MRI; however, this would require an MRI-compatible mouse hotel. Finally, analysis of nuclear images of radiopharmaceuticals in clinical trials may benefit from the automated analysis procedures developed.
引用
- Macholl S, Finucane CM, Hesterman J, et al. High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§. EJNMMI Res. 2017. PMID: 28389883. doi:10.1186/s13550-017-0281-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。